Your browser doesn't support javascript.
Down Syndrome and COVID-19: A Perfect Storm?
Espinosa, Joaquin M.
  • Espinosa JM; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Cell Rep Med ; 1(2): 100019, 2020 05 19.
Article in English | MEDLINE | ID: covidwho-2258429
ABSTRACT
People with Down syndrome show signs of chronic immune dysregulation, including a higher prevalence of autoimmune disorders, increased rates of hospitalization during respiratory viral infections, and higher mortality rates from pneumonia and sepsis. At the molecular and cellular levels, they show markers of chronic autoinflammation, including interferon hyperactivity, elevated levels of many inflammatory cytokines and chemokines, and changes in diverse immune cell types reminiscent of inflammatory conditions observed in the general population. However, the impact of this immune dysregulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and CoV disease of 2019 (COVID-19) remains unknown. This Perspective outlines why individuals with Down syndrome should be considered an at-risk population for severe COVID-19. Specifically, the immune dysregulation caused by trisomy 21 may result in an exacerbated cytokine release syndrome relative to that observed in the euploid population, thus justifying additional monitoring and specialized care for this vulnerable population.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Down Syndrome / Cytokine Release Syndrome / COVID-19 Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Cell Rep Med Year: 2020 Document Type: Article Affiliation country: J.xcrm.2020.100019

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Down Syndrome / Cytokine Release Syndrome / COVID-19 Type of study: Observational study / Prognostic study Limits: Humans Language: English Journal: Cell Rep Med Year: 2020 Document Type: Article Affiliation country: J.xcrm.2020.100019